

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August 2018

Commission File Number: 001-34541

**GLOBAL CORD BLOOD CORPORATION**

(Translation of registrant's name into English)

**48th Floor, Bank of China Tower**  
**1 Garden Road**  
**Central**  
**Hong Kong S.A.R.**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

---

**This report and each of the exhibits to this report are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-183143 and No. 333-213730) of the Company.**

**Other Events**

On August 17, 2018, Global Cord Blood Corporation (the "Company") issued a press release announcing the results of scrip dividend elections. Of the 120,824,742 ordinary shares of the Company outstanding as of July 30, 2018, the record date, holders of 87,523,354 ordinary shares notified the Company of their election to receive the dividend in the form of ordinary shares of the Company.

A copy of the press release is attached hereto as exhibit 99.1.

**Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated August 17, 2018, regarding results of scrip dividend elections.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLOBAL CORD BLOOD CORPORATION**

By: /s/ Albert Chen  
Name: Albert Chen  
Title: Chief Financial Officer

Dated: August 17, 2018



## Global Cord Blood Corporation Announces the Results of Scrip Dividend Elections

**HONG KONG, China, August 17, 2018 - Global Cord Blood Corporation** (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of the scrip dividend elections. The election period during which the Company provided to all of its shareholders the option to elect to receive, in cash or ordinary shares of the Company, a dividend payment of US\$0.08 per share ended at Noon Eastern Daylight Time on August 16, 2018. During the election period, of the 120,824,742 ordinary shares of the Company outstanding as of July 30, 2018, the record date, holders of 87,523,354 ordinary shares notified the Company of their election to receive the dividend in the form of ordinary shares of the Company.

As a result of these elections, the Company will issue a total of 726,333 ordinary shares and consequently the Company’s outstanding ordinary shares will consist of a total of 121,551,075 ordinary shares. The delivery of the newly issued ordinary shares as well as the payment of the cash distribution is expected to occur on August 20, 2018.

For more information regarding the scrip dividend, please visit the Company’s website at <http://ir.globalcordbloodcorp.com/phoenix.zhtml?c=206671&p=ir-dividends>.

### Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

### About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current People’s Republic of China government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at <http://www.globalcordbloodcorp.com>.

---

### For more information, please contact:

Global Cord Blood Corporation  
Investor Relations Department  
Tel: (+852) 3605-8180  
Email: [ir@globalcordbloodcorp.com](mailto:ir@globalcordbloodcorp.com)

ICR, Inc.  
Mr. William Zima  
Tel: (+86) 10-6583-7511  
U.S. Tel: (646) 405-5185  
Email: [William.zima@icrinc.com](mailto:William.zima@icrinc.com)

---